BioNTech (NASDAQ:BNTX) Releases Earnings Results, Beats Expectations By $0.95 EPS

BioNTech (NASDAQ:BNTX - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($1.82) earnings per share for the quarter, beating the consensus estimate of ($2.77) by $0.95, Zacks reports. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $197.76 million during the quarter, compared to analysts' expectations of $175.90 million. During the same quarter in the prior year, the firm posted ($1.31) earnings per share. The business's quarterly revenue was down 2.6% on a year-over-year basis. BioNTech updated its FY 2025 guidance to EPS.

BioNTech Trading Down 2.0 %

Shares of BioNTech stock traded down $1.94 on Wednesday, hitting $92.80. 1,049,437 shares of the company traded hands, compared to its average volume of 918,589. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a market cap of $22.27 billion, a PE ratio of -44.19 and a beta of 1.35. The stock's 50 day moving average price is $99.47 and its 200-day moving average price is $109.75. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on BNTX. Morgan Stanley lowered their price objective on BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a research note on Tuesday. Citigroup restated a "buy" rating and set a $140.00 target price (down from $145.00) on shares of BioNTech in a research report on Tuesday. Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Truist Financial initiated coverage on shares of BioNTech in a research report on Friday, January 10th. They set a "buy" rating and a $172.00 price objective on the stock. Finally, BMO Capital Markets upped their target price on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $142.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.